Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and ICU Medical (ICUI)

Tipranks - Sat Feb 21, 3:16AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Guardant Health (GHResearch Report) and ICU Medical (ICUIResearch Report) with bullish sentiments.

President's Day Sale - 70% Off

Guardant Health (GH)

In a report released today, Daniel Brennan from TD Cowen reiterated a Buy rating on Guardant Health, with a price target of $135.00. The company’s shares closed last Thursday at $106.38.

According to TipRanks.com, Brennan is a 5-star analyst with an average return of 19.2% and a 53.6% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $128.13, which is a 20.2% upside from current levels. In a report issued on February 17, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $120.00 price target.

See the top stocks recommended by analysts >>

ICU Medical (ICUI)

KeyBanc analyst Brett Fishbin maintained a Buy rating on ICU Medical today. The company’s shares closed last Thursday at $149.74.

According to TipRanks.com, Fishbin is a 1-star analyst with an average return of -4.4% and a 49.2% success rate. Fishbin covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Solventum Corporation, and LivaNova. ;'>

ICU Medical has an analyst consensus of Moderate Buy, with a price target consensus of $172.00, representing a 14.0% upside. In a report issued on February 18, Piper Sandler also maintained a Buy rating on the stock with a $172.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.